Skip to main content
4th of July Sale — Get 40% off Vantage subscriptions
Get Started
SubscribeLogin
Published • loading... • Updated

Zymeworks CEO on why the Theravance deal is value for money

Summary by endpoints.news
On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

endpoints.newsendpoints.news

Zymeworks CEO on why the Theravance deal is value for money

On the face of it, nearly $1 billion seems like a lot to spend on a biotech like Theravance. The company was clearly running out of steam, having twice downsized and been hit with repeated ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
4th of July SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news on Monday, June 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

South San Francisco icon

South San Francisco

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal